[go: up one dir, main page]

MX2009009344A - Formas solidas de un inhibidor de cinasa raf. - Google Patents

Formas solidas de un inhibidor de cinasa raf.

Info

Publication number
MX2009009344A
MX2009009344A MX2009009344A MX2009009344A MX2009009344A MX 2009009344 A MX2009009344 A MX 2009009344A MX 2009009344 A MX2009009344 A MX 2009009344A MX 2009009344 A MX2009009344 A MX 2009009344A MX 2009009344 A MX2009009344 A MX 2009009344A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
solid forms
raf kinase
imidazol
trifluoromethyl
Prior art date
Application number
MX2009009344A
Other languages
English (en)
Inventor
Ahmad Hashash
Kangwen L Lin
Augustus O Okhamafe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009009344A publication Critical patent/MX2009009344A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a las formas sólidas del inhibidor de cinasa Raf de 1-metil-5-(2-(5-(trifluoro-metil)-1H-im idazol-2-il)-piridin-4-iloxi)-N-(4-(trifluoro-metil)-fenil)-1 H-benzo-[d]imidazol-2-amina, así como a composiciones de las mismas y a la utilización de las mismas.
MX2009009344A 2007-03-02 2008-02-28 Formas solidas de un inhibidor de cinasa raf. MX2009009344A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90445507P 2007-03-02 2007-03-02
PCT/US2008/055227 WO2008140850A1 (en) 2007-03-02 2008-02-28 Solid forms of a raf kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2009009344A true MX2009009344A (es) 2009-09-11

Family

ID=39456506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009344A MX2009009344A (es) 2007-03-02 2008-02-28 Formas solidas de un inhibidor de cinasa raf.

Country Status (25)

Country Link
US (1) US8324389B2 (es)
EP (1) EP2132198A1 (es)
JP (1) JP2010520215A (es)
KR (1) KR20090117833A (es)
CN (1) CN101679372A (es)
AR (1) AR065565A1 (es)
AU (1) AU2008251764B2 (es)
BR (1) BRPI0808526A2 (es)
CA (1) CA2678335A1 (es)
CL (1) CL2008000616A1 (es)
CO (1) CO6230987A2 (es)
EC (1) ECSP099673A (es)
GT (1) GT200900237A (es)
IL (1) IL200441A0 (es)
MA (1) MA31259B1 (es)
MX (1) MX2009009344A (es)
MY (1) MY148438A (es)
NZ (1) NZ579084A (es)
PE (1) PE20081801A1 (es)
RU (1) RU2483064C2 (es)
SG (1) SG179423A1 (es)
TN (1) TN2009000356A1 (es)
TW (1) TW200846341A (es)
WO (1) WO2008140850A1 (es)
ZA (1) ZA200905618B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009147291A (ru) * 2007-05-23 2011-06-27 Новартис АГ (CH) Применение ингибиторов raf для лечения рака щитовидной железы
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
KR20180018800A (ko) * 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
RU2693004C1 (ru) * 2019-03-15 2019-07-01 Лейсан Фаридовна Минигулова Противоопухолевая композиция цисплатина с ингибитором 6-фосфоглюконатдегидрогеназы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7071216B2 (en) * 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
AU2007275634B2 (en) * 2006-07-21 2011-01-20 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
PE20130814A1 (es) * 2006-08-30 2013-08-08 Novartis Ag Sales de benzimidazolil piridil eteres y formulaciones que las contienen

Also Published As

Publication number Publication date
MY148438A (en) 2013-04-30
NZ579084A (en) 2012-04-27
AR065565A1 (es) 2009-06-17
ZA200905618B (en) 2010-05-26
TW200846341A (en) 2008-12-01
SG179423A1 (en) 2012-04-27
CO6230987A2 (es) 2010-12-20
CA2678335A1 (en) 2008-11-20
AU2008251764B2 (en) 2012-09-13
PE20081801A1 (es) 2009-01-08
KR20090117833A (ko) 2009-11-12
BRPI0808526A2 (pt) 2014-08-19
CL2008000616A1 (es) 2008-09-12
AU2008251764A1 (en) 2008-11-20
ECSP099673A (es) 2009-11-30
GT200900237A (es) 2010-06-24
US20100209418A1 (en) 2010-08-19
JP2010520215A (ja) 2010-06-10
IL200441A0 (en) 2010-04-29
RU2009136308A (ru) 2011-04-10
US8324389B2 (en) 2012-12-04
EP2132198A1 (en) 2009-12-16
WO2008140850A1 (en) 2008-11-20
MA31259B1 (fr) 2010-03-01
RU2483064C2 (ru) 2013-05-27
TN2009000356A1 (en) 2010-12-31
CN101679372A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
MX2009009344A (es) Formas solidas de un inhibidor de cinasa raf.
ZA201001513B (en) 5-(4-(Haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
MX2010004263A (es) Inhibidores de quinasa c-fms.
WO2007105058A3 (en) Pyrazole compounds
ZA200802636B (en) Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE)
MX2010001485A (es) Derivado de fenoxi-pirrolidina y su uso, y composiciones.
NZ594537A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
PH12013500649A1 (en) Crystalline (r)-(e)-2-(4-(2-(5-(1-(3, 5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol and its use as fgfr inhibitor
WO2008017361A3 (de) 2-(heterocyclylbenzyl)-pyridazinonderivate
IL229395A0 (en) Modified release of4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
NZ593969A (en) Pyrazine derivatives useful as inhibitors of atr kinase
WO2008059029A3 (en) New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate
SI2632921T1 (sl) Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
WO2006047503A3 (en) Inhibitors of c-fms kinase
PE20080038A1 (es) Derivados de tiazolidinadiona como inhibidores de la pi3 quinasa
NZ596607A (en) Anthelmintic agents and their use
WO2008019030A3 (en) Modified azole compounds as antiinfective agents
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
MD4215B1 (en) Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
NZ600782A (en) New secondary 8-hydroxyquinoline-7-carboxamide derivatives.
WO2011084652A3 (en) Crystalline salts of a factor xa inhibitor
WO2013120852A4 (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
TW200612944A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration